ACTIVE THERAPEUTIC PROGRAM · DENGUE & FLAVIVIRUSES
Dengue has expanded dramatically across the world. WHO recorded unprecedented global transmission in 2024, while continued outbreaks demonstrate the need for new antiviral options. UDD is actively applying fast, scalable and innovative discovery capabilities to dengue and other medically important flaviviruses.
.jpg)
Real transmission electron micrograph · CDC / NIAID · CC BY 2.0
WHO GLOBAL DENGUE SURVEILLANCE
WHO reports that the Americas accounted for more than 90% of global reported cases in 2024. This interactive map displays selected country totals reported in WHO's 2024 epidemiological update; grey countries should not be interpreted as having no dengue.
Reported dengue cases more than doubled from the previous record year, illustrating the scale of the recent global surge.
Reported cases from WHO's global epidemiological update.
WHO recorded the highest dengue burden in history in 2024. Transmission has expanded into new geographical and climatic zones, driven by changing vector distribution, climate conditions, urbanization, travel and vulnerable health systems. From January–June 2026, WHO received reports of about 1.6 million cases and more than 700 deaths from 89 countries and territories; seasonal peaks differ across regions, so partial-year comparisons require caution.
UDD is using rapid, scalable computational discovery to search broad molecular space and prioritize candidates against flaviviral targets. The program is designed to accelerate the path from molecular possibilities to scientifically prioritized candidates while keeping proprietary discovery methods confidential.
Data sources: WHO — Dengue global situation, surveillance and progress: 2024 update ↗ · WHO Dengue fact sheet ↗